Is suppression of cyst growth in PKD enough to preserve renal function?: STAT6 inhibition is a novel promising target
The autosomal dominant form of polycystic kidney disease (ADPKD) is one of the most frequent monogenic disorders and the most frequent among inherited kidney disorders. In fact it has a prevalence in the population of about 1/1,000 individuals, therefore it does not even satisfy the definition for r...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670250/ |
| id |
pubmed-3670250 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-36702502013-09-19 Is suppression of cyst growth in PKD enough to preserve renal function?: STAT6 inhibition is a novel promising target Deltas, Constantinos Felekkis, Kyriacos Commentary The autosomal dominant form of polycystic kidney disease (ADPKD) is one of the most frequent monogenic disorders and the most frequent among inherited kidney disorders. In fact it has a prevalence in the population of about 1/1,000 individuals, therefore it does not even satisfy the definition for rare diseases. It is mainly characterized by the formation of multiple cysts filled with fluid that over time develop in number and size leading to the distraction of the structure and function of the kidneys and eventually leading to chronic kidney disease/end stage kidney disease (CKD/ESKD), usually between the 4th and 7th decade of life. There are two known forms of the autosomal dominant type of polycystic kidney disease, type 1 and type 2, caused by mutations in the PKD1 and PKD2 genes, located on chromosomes 16 and 4 respectively. The polycystin 1 protein, encoded by PKD1 and mutated in ~85% of patients, is a huge protein of 4,302 amino acids with multiple transmembrane domains, 200 residues intracytoplasmic part and a huge extracellular part with multiple Ig-like PKD repeats, which probably acts as a receptor to an unknown ligand. Polycystin 1 has been shown to interact with and participate in multiple signal transduction pathways, including the G-protein coupled receptor, cAMP pathway, Wnt, mTOR, MAPK/ERK, AP1 and JAK-STAT pathway, while its intracytoplasmic C-terminal domain has been shown to be cleaved and translocated to the nucleus where it plays a role in gene transcription, in concert with P100 and STAT6.1 Landes Bioscience 2012-07-01 2012-07-01 /pmc/articles/PMC3670250/ /pubmed/24058776 http://dx.doi.org/10.4161/jkst.21634 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Deltas, Constantinos Felekkis, Kyriacos |
| spellingShingle |
Deltas, Constantinos Felekkis, Kyriacos Is suppression of cyst growth in PKD enough to preserve renal function?: STAT6 inhibition is a novel promising target |
| author_facet |
Deltas, Constantinos Felekkis, Kyriacos |
| author_sort |
Deltas, Constantinos |
| title |
Is suppression of cyst growth in PKD enough to preserve renal function?: STAT6 inhibition is a novel promising target |
| title_short |
Is suppression of cyst growth in PKD enough to preserve renal function?: STAT6 inhibition is a novel promising target |
| title_full |
Is suppression of cyst growth in PKD enough to preserve renal function?: STAT6 inhibition is a novel promising target |
| title_fullStr |
Is suppression of cyst growth in PKD enough to preserve renal function?: STAT6 inhibition is a novel promising target |
| title_full_unstemmed |
Is suppression of cyst growth in PKD enough to preserve renal function?: STAT6 inhibition is a novel promising target |
| title_sort |
is suppression of cyst growth in pkd enough to preserve renal function?: stat6 inhibition is a novel promising target |
| description |
The autosomal dominant form of polycystic kidney disease (ADPKD) is one of the most frequent monogenic disorders and the most frequent among inherited kidney disorders. In fact it has a prevalence in the population of about 1/1,000 individuals, therefore it does not even satisfy the definition for rare diseases. It is mainly characterized by the formation of multiple cysts filled with fluid that over time develop in number and size leading to the distraction of the structure and function of the kidneys and eventually leading to chronic kidney disease/end stage kidney disease (CKD/ESKD), usually between the 4th and 7th decade of life. There are two known forms of the autosomal dominant type of polycystic kidney disease, type 1 and type 2, caused by mutations in the PKD1 and PKD2 genes, located on chromosomes 16 and 4 respectively. The polycystin 1 protein, encoded by PKD1 and mutated in ~85% of patients, is a huge protein of 4,302 amino acids with multiple transmembrane domains, 200 residues intracytoplasmic part and a huge extracellular part with multiple Ig-like PKD repeats, which probably acts as a receptor to an unknown ligand. Polycystin 1 has been shown to interact with and participate in multiple signal transduction pathways, including the G-protein coupled receptor, cAMP pathway, Wnt, mTOR, MAPK/ERK, AP1 and JAK-STAT pathway, while its intracytoplasmic C-terminal domain has been shown to be cleaved and translocated to the nucleus where it plays a role in gene transcription, in concert with P100 and STAT6.1 |
| publisher |
Landes Bioscience |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670250/ |
| _version_ |
1611982947398713344 |